点击查看高清原图
在法国里昂，合生元与梅里埃营养科学集团旗下的生物福提斯成功签署了微生态研究的技术转让协议。
合生元创建于1999年，现有2500名员工，为中国市场提供高端的婴幼儿营养品及护理品。合生元专注于高端消费者，并致力于通过与全球领先的合作伙伴进行联合研发的方式来为消费者们提供全方位的优质产品。生物福提斯是梅里埃营养科学集团旗下的一家子公司，致力于食品、营养、健康，化妆品和日用消费品的创新。两家公司签署的战略合作协议将促使合生元在广州的新技术中心搭建起一个高效能的微生态宏基因组学技术平台。
宏基因组学是一种可以通过分析肠道菌群来详细了解营养和健康状况之间关系的新技术。最近研究显示肠道菌群可以通过与大脑的通信作用从而对肥胖，炎性疾病，压力和行为产生重要作用。凭借先进的高通量宏基因组学技术，能够帮助我们详细了解肠道微生态的状态和组成，基于此技术开展相关研究，对于更好了解肠道功能，促进健康，甚至制定个性化的营养建议，具有重要的意义。
合生元首席技术执行官暨BINC执行理事Patrice Malard表示，“微生态宏基因组学不仅是生命科学的一项新革命，还是针对我们的目标市场开发创新和适宜的营养产品的绝佳工具。与此同时，该微生态宏基因组学技术平台也将作为我们新近成立的合生元营养与护理研究院(BINC)的一部分，极大的促进与中国科学界和医学界在科学研究中的合作。”
生物福提斯的首席科学执行官Francoise Le Vacon 说：“与合生元的合作是一个双赢的局面，而且生物福提斯未来还可以借助这个平台开展自身在中国的研究。生物福提斯作为梅里埃研究所的一部分已经在中国发展超过30年，并且致力于为中国科学家的营养研究作贡献。”
梅里埃集团在微生物鉴定技术领域居于世界领先地位，生物福提斯通过临床研究已经将该技术转化到行业应用中。基于该技术转让合作，合生元营养与护理研究院的微生态宏基因组学技术平台将全面接轨世界领先的技术，为未来的研究和开发奠定坚实基础。
Biostime and Biofortis, a Mérieux NutriSciences company, signed a technology transfer agreement in the field of microbiota research for the Chinese Market
Biostime and Biofortis signed on September 30, 2014 a technology transfer agreement in the field of microbiota research in Lyon Frence。
Created in 1999 and employing 2500 employees, Biostime is a premium pediatric nutrition and baby care products provider in China. The Company focuses on high-end consumers and strives to offer them a full range of quality products through joint research and development with global leading partners. Biofortis is Mérieux NutriSciences’ Contract Research Organization serving innovation in food, nutrition, health, cosmetics and consumer goods. Together, the companies signed a strategic agreement that will enable to develop a high performance metagenomics platform in Biostime’s new technology center in Guangzhou (China)。
metagenomics are new technologies allowing a detailed understanding of the relationship between nutrition and health conditions through the analysis of the gut microbiota. Gut microbiota has been recently shown as playing an essential role in obesity, inflammatory diseases but also in stress and behavior through its communication with the brain。
“metagenomics is definitely the new revolution in life science and a tremendous opportunity to develop innovative and adapted nutritional products for our target market. It is also a fantastic tool that will allow us to collaborate with the scientific and medical community in China as part of our newly launched Biostime Institute for Nutrition and Care”， said Patrice Malard, Chief Technology Officer at Biostime。
Biofortis has one of the largest expertise in Europe of these new technologies and already supports the industry through its clinical research activities. “The cooperation with Biostime is a win win situation for both companies as Biofortis may also use this platform in the future for its own research inChina. As part of Institut Mérieux which has already more than 30 years of presence in China we strive to contribute to the nutritional research efforts of Chinese scientists”， said Francoise Le Vacon, Chief Scientific Officer of Biofortis。
